Novocure Limited's average 12-month price target has been raised to $22.2 by five analysts, implying a 52% upside. The consensus rating remains a 'Buy,' suggesting continued analyst confidence despite mixed individual ratings.
Novocure Limited has seen its average 12-month price target increased to $22.2 by a consensus of five analysts, representing a significant potential upside of 52% from its November 4, 2026 closing price. This update reflects a generally positive outlook from the analyst community, as the consensus rating remains a 'Buy,' even with a split of three 'Buy' and three 'Hold' ratings among six covering analysts. For traders, this indicates a potential short-term positive sentiment boost for NVCR, driven by the higher price target. The long-term implications depend on the company's ability to meet or exceed these analyst expectations, with the key opportunity being the substantial implied upside if the company performs well.